AstraZeneca and Regeneron to develop obesity treatments

Updated: Aug 3

AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits.

The new target was found by sequencing nearly 650,000 people and identifying individuals with rare protective mutations. Individuals with at least one inactive copy of the GPR75 gene had lower body mass index (BMI) and, on average, tended to weigh about 12 pounds less and faced a 54% lower risk of obesity than those without the mutation (Akbari P et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science. 2021). Strong associations were also seen with improvements in diabetes parameters, including glucose lowering.


“We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca. “Obesity and insulin resistance remain key drivers in the development of type-2 diabetes and areas of significant unmet medical need.”

“The next era of drug development is being fueled by important genetic findings that direct drug developers on how to deploy our toolkit of biologics, small molecules and gene editing technologies,” added Dr George D Yancopoulos, President and Chief Scientific Officer of Regeneron “As experts on genetics and human biology, Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca, as we seek to develop new medicines tackling the harmful and costly obesity epidemic.”